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Hypoglycaemia classification
  Hypoglycaemia was defined and classified as follows:
 –  Severe hypoglycaemia was defined as per the American Diabetes Association 
(ADA) definition (requiring third party assistance)7
 –  Any hypoglycaemia – the sum of severe and non-severe hypoglycaemia
 –  Nocturnal hypoglycaemia – hypoglycaemia occurring between midnight and 
06.00 h
Statistical analyses
  All statistical tests were two-sided and regarded as exploratory, with the criterion 
for statistical significance set at p<0.05. No adjustments were made for multiple 
comparisons
  The percentage of patients experiencing at least one hypoglycaemic event during 
the observation period was calculated together with the 95% confidence interval 
(CI) for this percentage, assuming a binomial distribution
  Negative binomial regression models stratified by country and specifying a log-
transformed exposure time offset term were used to examine the relationship 
between various factors and the incidence of hypoglycaemia
Results
Patient characteristics
2056 patients in Germany completed the study. The patient characteristics for the 
population are summarised in Table 1.
Table 1 Characteristics of patient population
Characteristic
T1D  
(n=811)
T2D  
(n=1619)
Number of patients who completed part 2 SAQ, n (%) 641 (79.0) 1415 (87.4)
Number of patients who completed patient diary, n (%) 640 (78.9) 1404 (86.7)
Sex male/female, % 51/49 54/46
Mean age, years (SD) 47.8 (14.7) 66.3 (10.5)
Duration of diabetes, years (SD) 19.9 (12.8) 15.4 (8.8)
HbA1c, mmol/mol (SD) 59.6 (13.8) 58.3 (13.6)
HbA1c, %* 7.6 7.5
Method of diabetes treatment, n (%)
Short-acting insulin 671 (82.9) 1237 (77.0)
Long-acting insulin 517 (63.9) 1348 (83.9)
Mixed insulin 7 (0.9) 129 (8.0)
Insulin pump 228 (28.2) 15 (0.9)
Oral antidiabetes treatments 17 (2.1) 449 (27.9)
Injectable antidiabetes treatments excluding insulin 0 (0.0) 27 (1.7)
Use of continuous glucose monitoring device, n (%)
Yes 306 (38.3) 843 (52.4)
No 490 (61.3) 754 (46.9)
Not sure 4 (0.5) 12 (0.7)
Checks blood sugar levels, n (%)
Yes 806 (99.4) 1597 (98.8)
No 5 (0.6) 20 (1.2)
Experienced hypoglycaemia, n (%)
Yes 780 (97.1) 1224 (76.3)
No 13 (1.6) 322 (20.1)
Not sure 10 (1.2) 58 (3.6)
*Calculated, not measured
Full analysis set. SAQ, self-assessment questionnaire; SD, standard deviation; T1D, type 1 diabetes; T2D, 
type 2 diabetes
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Overall hypoglycaemia frequency
  Prospective and retrospective hypoglycaemia incidence and prevalence are shown 
in Table 2
 –  Self-reported hypoglycaemia rates in T1D and T2D during the prospective period 
are shown in Figure 1
Table 2 Hypoglycaemia incidence and prevalence in retrospective and 
prospective periods
Retrospective Prospective
T1D T2D T1D T2D
Hypoglycaemia prevalence, % of patients
Any (4 weeks) 82.8 45.3 81.3 39.7
Nocturnal (4 weeks) 43.2 16.5 37.3 12.2
Severe 23.5* 9.9* 9.1† 5.4†
Hypoglycaemia incidence, events per patient year 
Any (4 weeks) 50.0 11.2 80.3 15.6
Nocturnal (4 weeks) 14.4 3.6 9.9 2.4
Severe 2.1* 0.4* 3.0† 1.1†
*6-month period, †4-week period
T1D, type 1 diabetes; T2D, type 2 diabetes
Incidence and prevalence calculated from full analysis set
Figure 1 Self-reported hypoglycaemia rates in the 4-week prospective period
  The incidence rate ratio for any hypoglycaemia in the prospective/retrospective periods 
(calculated from completer population) was 1.62 (95% CI 1.42, 1.85) for T1D and 1.39 
(95% CI 1.23, 1.56) for T2D
  64.2% of all patients identified hypoglycaemia by symptoms and blood glucose 
measurements
Associations between hypoglycaemia and continuous or predictor 
variables
  Fully-adjusted negative binomial modelling showed only a weak association between 
any hypoglycaemia and HbA1c levels (incidence rate ratio [IRR] 0.99; 95% CI 0.99, 
0.99)
  The proportions of T1D and T2D patients with hypoglycaemia incidence by HbA1c 
level is shown in Figure 2
Figure 2 Proportions of patients with hypoglycaemia by HbA1c level in patients 
with (a) type 1 diabetes (T1D) and (b) type 2 diabetes (T2D) 
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Introduction
  There is limited evidence from observational studies regarding rate of hypoglycaemia 
in clinical practice
 –  International prospective studies have reported a hypoglycaemia frequency of 
3.9–7.2 events/month for T1D1–3 and 0.76–3.7 events/month for T2D1–6
 –  The wide range of reported hypoglycaemia incidence in T2D highlights the need 
for additional data to determine factors associated with hypoglycaemia risk
  The global Hypoglycaemia Assessment Tool (HAT) study was designed to determine 
the extent of hypoglycaemia experienced in a global insulin-treated patient popula-
tion; this analysis presents data from the German population. Predictive and con-
tinuous factors contributing to hypoglycaemia risk were also explored
Materials and methods
Study design
  Non-interventional, multicentre, 6-month retrospective and 1-month prospective 
study of hypoglycaemic events, conducted in 24 countries using self-assessment 
questionnaires (SAQs) and patient diaries (for the 28-day prospective period)
Study objectives
  Primary endpoint: percentage of patients experiencing at least one hypoglycaemic 
event during the observational period
 Secondary endpoints included:
 –  Hypoglycaemia incidence rates
 –  Relationship between hypoglycaemia and predictive or continuous factors such 
as age, gender, duration of insulin use or HbA1c
Study population
  Consecutive eligible patients were enrolled during a routinely scheduled clinical 
consultation with their healthcare provider
  Inclusion criteria:
 –  Patients with T1D or T2D treated with insulin for >12 months
 –  Patients ≥18 years of age at the time of survey
 –  Patients giving informed consent to participate in the survey
In Germany, 2430 (T1D 811; T2D 1619) patients at 176 sites participated in the study
Assessments
  Two-part SAQ
 –  Part 1 (first visit): Baseline demographic and treatment information, knowledge, 
hypoglycaemia unawareness, perceptions of hypoglycaemia, history of severe 
hypoglycaemia over the previous 6 months, symptomatic hypoglycaemia over 
the previous 4 weeks
 –  Part 2 (second visit): History of both severe and symptomatic hypoglycaemia over 
the 4 weeks following study entry, effect of hypoglycaemia on productivity, 
healthcare utilisation and productivity during this period
  Differences in reported hypoglycaemia in the retrospective and prospective 
periods were used to estimate under-reporting
  Hypoglycaemia unawareness was evaluated through the self-assessment 
question: ‘Do you have symptoms when you have a low sugar level?’, where the 
response, ‘occasionally’ denotes impaired awareness, and ‘never’ denotes severely 
impaired awareness
  A patient diary was used to assist recall and record hypoglycaemic events
Conclusions
   This large retrospective and prospective study 
determined the extent of hypoglycaemia 
experienced by insulin-treated T1D and T2D 
patients in the German population
   Estimated rates of overall, nocturnal and severe 
hypoglycaemia were higher than previously 
reported1–6
   An increased incidence of overall hypoglycaemia 
in the prospective study compared to the 
retrospective reports indicated under-reporting 
of hypoglycaemia
   There were no strong associations between 
hypoglycaemia and the predictor variables 
 studied 
   These findings highlight the need for clinicians 
to tailor insulin treatment to individual patients 
with diabetes
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  Age was weakly correlated with the rate of any hypoglycaemic events (IRR 0.98; 
95% CI 0.98, 0.99)
  Females were more likely to report hypoglycaemia overall than males (IRR 1.30; 
95% CI 1.15, 1.46)
  Patients with hypoglycaemia unawareness – specifically, those who occasionally/
never have symptoms with low blood glucose measurement – were less likely to 
report incidence of any hypoglycaemic event (IRR 0.87; 95% CI 0.72, 1.05)
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